Albright hereditary osteodystrophy (AHO) is an autosomal dominant disorder characterised by the presence of bra-
chymetaphalangism, short stature, obesity, and mental retardation. Variable biochemical changes may represent either pseudohypoparathyroidism (PHP) owing to resistance to parathormone (PTH) or pseudopseudohypoparathyroidism (PPHP) with no hormone resistance. In most cases of AHO, reduced levels of Gsa have been found and a number of deactivating mutations in the gene for Gsa located on chromosome 20q13 have been described. Recently a number of people with an AHO-like phenotype have been reported in whom a deletion of chromosomal region 2q37 has been found in the absence ofbiochemical abnormalities or a reduction in Gsa activity.
We present a further female patient with a cytogenetically visible deletion of 2q37, an AHO-like phenotype, and unusual biochemistry suggesting moderate PTH resistance. The vasoactive intestinal peptide receptor (RDCI) has recently been mapped to 2q37 and we propose that this is a candidate gene, hemizygosity of which affects signal transduction and leads to the AHO-like phenotype found in patients with 2q37 deletions. ( There was a younger male sib who was well.
A squint was noted in this girl in the neonatal period, as were bilateral toe deformities, including short fourth metatarsals bilaterally, more pronounced on the right. At 2 months of age she was noted to be hypotonic and feeding poorly. She was unable to sit unsupported until 18 months of age and did not walk independently until 4 years of age. She had marked learning difficulties and attended a special school for children with learning difficulties. Until puberty (at the age of 13 years), her height was on the 25th centile and her weight was on the 90th centile. When assessed at the age of 18, her height was below the 3rd centile while her weight was significantly above the 97th centile. In addition to short stature and gross obesity, particularly involving the lower deletion in two previously reported cases from our laboratory in which the AHO phenotype has yet to be fully investigated.'2 One case showed a maternal deletion and one had a paternal deletion (R S James, unpublished data). These results would seem to exclude any simple imprinting effect in this condition. A further 13 group.bmj.com on October 28, 2017 -Published by http://jmg.bmj.com/ Downloaded from Power et al D2S 125, the most telomeric 2q marker described.5 Molecular analysis confirms that the subject of this report has inherited only paternal copies of two distal microsatellite alleles including D2S 125, confirming that the MRO is deleted in this case. These data suggest the presence of a candidate gene or genes in the 2q37.3 region which may be involved in hormone signal transduction. Haploinsufficiency of these genes may provide an alternative pathway for development of an AHO-like phenotype.
Vasoactive intestinal peptide (VIP) is a neuroendocrine mediator found in the central and peripheral nervous system. RDCI has recently been identified as the VIP receptor and has been cloned and mapped to 2q37.4 25 It is a member of the G protein coupled receptor family whose effect is to increase intracellular cAMP via activation of adenyl cyclase. VIP has been shown to be a potent activator of adenyl cyclase in many systems. In particular it has been shown that in in vitro organ cultures VIP acts to enhance bone resorption via a cAMP dependent mechanism which is similar to that induced by PTH. '6 In addition, raised levels of VIP are found in the rare non-beta islet cell tumours of the pancreas known as vipomas (Verner-Morrison syndrome) and associated with hypercalcaemia in 75% of patients.27
Raised levels of VIP resulting in increased stimulation of intracellular cAMP via the VIP receptor could, therefore, be the cause of the majority of hypercalcaemic vipoma patients in whom hypercalcaemia cannot be explained by concomitant parathyroid hyperplasia. In the case of deletion of 2q37 leading to hemizygosity of the VIP receptor, an equivalent but opposite effect on calcium metabolism may therefore provide an alternative aetiology for the AHO phenotype. In particular, a reduction of VIP receptor sites may lead to an increase in PTH via a feedback mechanism consistent with the moderately raised PTH levels in the subject of this report. The implication of this proposal is that VIP and its receptor are required for calcium homeostasis.
No syndrome has as yet been associated with a deficiency of VIP itself, which has been mapped to 6q26-27."' It may be, however, that microdeletion or other mutations of this region are implicated in some cases of AHO that are not caused by either deactivating mutations in Gsa at 20q13 or deletion of 2q37.
